Real-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment
/0 Comments/in Retrospective studies/by MaxRetrospective Study On Real World Data: Sipuleucel-T Shows Encouraging Results in mCRPC
/0 Comments/in Retrospective studies/by MaxReal-World Prostate Cancer Treatments Are Better Than Clinical Trial Results, Study Finds
/0 Comments/in Retrospective studies/by MaxEnzalutamide Boosts PSA Control in High-Risk Prostate Cancer: Insights from the EMBARK Trial
/0 Comments/in Post-hoc, Retrospective studies/by MaxNew Study Reveals Key Factors That Influence How Quickly Prostate Cancer Becomes Resistant to Hormone Therapy
/0 Comments/in Retrospective studies/by MaxASCO GU 2025: Continuous ADT Remains Superior to Intermittent Therapy in Metastatic Hormone-Sensitive Prostate Cancer
/0 Comments/in Retrospective studies/by MaxASCO GU 2025: Lu-PSMA Therapy Outperforms Cabazitaxel in Advanced Prostate Cancer, Real-World Evidence
/0 Comments/in Retrospective studies/by MaxUndetectable PSA Nadir Linked to Better Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Real-World Data from IRONMAN Registry
/0 Comments/in Retrospective studies/by MaxASCO GU 2025: Impact of Homologous Recombination Repair Alterations on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (BRCA, ATM, CDK12,…)
/0 Comments/in Observational, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- AI Platform Aims to Revolutionize Cancer Immunotherapy July 28, 2025
- FDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors July 28, 2025
- Phase 1 Trial For BL-M14D1 For Neuroendocrine Cancers July 28, 2025
- Newsletter 30/2025 July 27, 2025